ClinicalTrials.gg
CompletedNCT00832819Updated Apr 30, 2015Results posted

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

A Phase 1 interventional study of E7080 and E7080 in Non-small-cell Lung Cancer, sponsored by Eisai Co., Ltd.. Completed at 3 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2015-04-30.

Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment

How we know · 10 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 4 under way, 1 of them phase 3. lenvatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
8th of 14
28 · median 29
Started
2009
the only one that year
Phase 1
2 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
2 of 14
Eisai Co., Ltd.

Among the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, this one is the 8th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 1, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to determined the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 administered continually twice daily in combination with carboplatin and paclitaxel to patients with advanced or metastatic non-small cell lung cancer.

03

Conditions studied

  • Non-small-cell Lung Cancer

Keywords

  • Cancer
  • Lung Cancer
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with a or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).
  2. Locally advanced and/or non-small cell lung cancer (NSCLC) (Stage IIIB/IV).
  3. Subjects with at least one measurable tumor lesion by (RECIST).
  4. Subjects with Performance Status (PS) 0-1.
  5. Subjects with adequate organ function.

Exclusion criteria

Exclusion criteria:

  1. Subjects who have ever received the following therapy for non-small cell lung cancer (NSCLC):

    1. Chemotherapy
    2. Biological or immunotherapies
    3. Surgery for primary focus
    4. The radiation therapy for primary focus
  2. Subjects with the severe complications or disease history.
  3. Subjects with accompanying clinical symptoms or requiring treatment.
  4. Subjects with simultaneous or metachronous cancers.
  5. Subjects who cannot take oral medication.
  6. Subjects who are using drugs that strongly inhibit or induce cytochrome P450 (CYP) 3A4.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    E7080 (Dose Escalation Cohort)

    This will be a dose-escalation evaluation of 12-18 participants to determine the maximum tolerated dose of E7080 in combination with paclitaxel and carboplatin.

    Drug: E7080 · Drug: Paclitaxel · Drug: Carboplatin

  • Experimental
    E7080 (Expansion Cohort)

    Dosage of E7080 for Expansion Cohort will be determined based on the maximum tolerated dose in the Dose-Escalation Cohort.

    Drug: E7080 · Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • DrugLenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).

  • DrugLenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).

  • Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.

  • Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    Tolerability was confirmed by the frequency of occurrence of Dose Limiting Toxicities (DLTs) observed by the end of Cycle 1 in 6 participants.

    Time frame: 7 days during the run-in period (Cycle 0) and 3 weeks (21 days) from Cycle 1

Secondary outcomes

  1. Anti-tumor Effect of E7080 in Combination With Carboplatin and Paclitaxel.

    Time frame: At Screening, on Day 22 of every even cycle, and at discontinuation

  2. Pharmacokinetics and Pharmacodynamics of E7080 in Combination With Carboplatin and Paclitaxel.

    Time frame: At various time points until Day 22 of Cycle 1

  3. To Evaluate the Safety and Tolerability of E7080 in Combination With Carboplatin and Paclitaxel.

    Refer safety section for safety analysis

    Time frame: Throughout the study until 30 days after last dose

07

Results

Posted Mar 6, 2015

Participant flow

Participant flow — Overall Study
MilestoneE7080 4 mg BID (Dose Escalation)E7080 6 mg BID (Dose Escalation)E7080 4 mg BID (Expansion)
Started6616
Completed6515
Not completed011
Withdrew: Adverse event010
Withdrew: Protocol violation001

Outcome measures

SecondaryAnti-tumor Effect of E7080 in Combination With Carboplatin and Paclitaxel.
Time frame:
At Screening, on Day 22 of every even cycle, and at discontinuation

Results for this outcome have not been posted.

PrimaryMaximum Tolerated Dose (MTD)

Tolerability was confirmed by the frequency of occurrence of Dose Limiting Toxicities (DLTs) observed by the end of Cycle 1 in 6 participants.

Time frame:
7 days during the run-in period (Cycle 0) and 3 weeks (21 days) from Cycle 1
Reported as:
Number · mg BID
Maximum Tolerated Dose (MTD)
mg BIDE7080 6 mg BID (Dose Escalation)
Maximum Tolerated Dose (MTD)4
SecondaryPharmacokinetics and Pharmacodynamics of E7080 in Combination With Carboplatin and Paclitaxel.
Time frame:
At various time points until Day 22 of Cycle 1

Results for this outcome have not been posted.

SecondaryTo Evaluate the Safety and Tolerability of E7080 in Combination With Carboplatin and Paclitaxel.

Refer safety section for safety analysis

Time frame:
Throughout the study until 30 days after last dose

Results for this outcome have not been posted.

Adverse events

Collected over Throughout the study until 30 days after last dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E7080 4 mg BID (Dose Escalation)—3/6 (50%)6/6 (100%)
E7080 6 mg BID (Dose Escalation)—2/6 (33.3%)6/6 (100%)
E7080 4 mg BID (Expansion)—6/16 (37.5%)16/16 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventE7080 4 mg BID (Dose Escalation)E7080 6 mg BID (Dose Escalation)E7080 4 mg BID (Expansion)
SyncopeNervous system disorders0/61/60/16
WoundInjury, poisoning and procedural complications0/61/60/16
HaematomaVascular disorders0/61/60/16
PneumoniaInfections and infestations1/61/60/16
Lymphangiosis carcinomatosaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/60/60/16
Decreased AppetiteMetabolism and nutrition disorders1/60/60/16
PyelonephritisInfections and infestations1/60/60/16
Febrile neutropeniaBlood and lymphatic system disorders0/60/62/16
VomitingGastrointestinal disorders0/60/61/16
Abdominal painGastrointestinal disorders0/60/61/16
Most frequent other events
Showing 10 of 146
Most frequent other events
EventE7080 4 mg BID (Dose Escalation)E7080 6 mg BID (Dose Escalation)E7080 4 mg BID (Expansion)
LeukopeniaBlood and lymphatic system disorders6/65/615/16
NeutropeniaBlood and lymphatic system disorders6/65/615/16
ThrombocytopeniaBlood and lymphatic system disorders6/64/616/16
DiarrhoeaGastrointestinal disorders6/64/612/16
NauseaGastrointestinal disorders5/66/613/16
Aspartate aminotransferase increasedInvestigations4/66/65/16
ArthralgiaMusculoskeletal and connective tissue disorders5/65/616/16
Peripheral sensory neuropathyNervous system disorders6/65/615/16
ProteinuriaRenal and urinary disorders6/63/611/16
AlopeciaSkin and subcutaneous tissue disorders6/65/615/16

Baseline characteristics

Age, Continuous
Age, Continuous(Years)E7080 4 mg BID (Dose Escalation)E7080 6 mg BID (Dose Escalation)E7080 4 mg BID (Expansion)Total
Mean52.8 ± 9.354.8 ± 9.758.4 ± 11.256.4 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)E7080 4 mg BID (Dose Escalation)E7080 6 mg BID (Dose Escalation)E7080 4 mg BID (Expansion)Total
Female2237
Male441321
08

Study locations

3 sites
  • Sunto-gun, Shizuoka, Japan
  • Chuo-ku, Tokyo, Japan
  • Koto-ku, Tokyo, Japan
09

References and documents

Publications

  • Nishio M, Horai T, Horiike A, Nokihara H, Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio K, Yusa W, Koyama N, Tamura T. Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br J Cancer. 2013 Aug 6;109(3):538-44. doi: 10.1038/bjc.2013.374. Epub 2013 Jul 16. PubMed 23860537 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Jul 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2009
First posted
Jan 30, 2009
Start
Feb 2009
Primary completionActual
Jul 2011
CompletionActual
Oct 2011
Results first posted
Mar 6, 2015
Last update
Apr 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00832819
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Jan 30, 2009
Start date
Feb 2009
Primary completion
Jul 2011
Completion
Oct 2011
Results posted
Mar 6, 2015
Last update
Apr 30, 2015

Study contacts

Wataru Yusa
study director · Oncology Clinical Development Section. JAC PCU. Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion